fingolimod stada 0,5 mg tvrdé kapsuly
stada arzneimittel ag, nemecko - fingolimod - 59 - immunopraeparata
fingolimod zentiva 0,5 mg
zentiva, k.s., Česká republika - fingolimod - 59 - immunopraeparata
golpimec 0,5 mg tvrdé kapsuly
neuraxpharm bohemia s.r.o., Česká republika - fingolimod - 59 - immunopraeparata
inzolfi 0,5 mg tvrdé kapsuly
sandoz pharmaceuticals d.d., slovinsko - fingolimod - 59 - immunopraeparata
fingolimod richter 0,5 mg tvrdé kapsuly
gedeon richter plc., maďarsko - fingolimod - 59 - immunopraeparata
fingolimod reddy 0,5 mg tvrdé kapsuly
reddy holding gmbh, nemecko - fingolimod - 59 - immunopraeparata
fimodigo 0,5 mg
vipharm s.a., poľsko - fingolimod - 59 - immunopraeparata
lognif 0,5 mg tvrdé kapsuly
teva pharmaceuticals slovakia s.r.o., slovensko - fingolimod - 59 - immunopraeparata
tysabri
biogen netherlands b.v. - natalizumab - roztrúsená skleróza - selektívne imunosupresíva - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 a 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
victrelis
merck sharp dohme ltd - boceprevir - hepatitída c, chronická - antivirotiká na systémové použitie - victrelis je indikovaný na liečbu chronickej hepatitídy c (chc) genotypu 1 infekcie, v kombinácii s peginterferónom alfa a ribavirínom u dospelých pacientov s kompenzovaným ochorením pečene, ktorí neboli predtým liečení alebo ktorí zlyhala predchádzajúca liečba.